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Abstract: 
The current study was conducted to evaluate the effect of 6-gingerol (6G) on cardiac 
complications in streptozotocin (STZ)-induced diabetic (DM) rats.  STZ-induced DM rats (single 
50mg/kg i.p. injection, 15 days prior to drug treatment) or time-matched controls were treated 
with 6G (75 mg/day route orally).  After a further 8 weeks, blood was collected for biochemical 
analysis and 8-isoprostenol was measured in urine. Cardiac hemodynamics and ECG was 
assessed. 6G significantly attenuated the increased level of blood glucose in diabetic rats and 
improved cardiac hemodynamics in including RR interval, max dP/dt, min dP/dt and Tau. In 
addition, 6G alleviated the elevated ST segment, T amplitude and R amplitude with no 
significant effect on disturbed levels of adiponectin, TGF-β or 8-isoprostenol induced by 
diabetes. The results showed that treatment with 6G has an ameliorative effect on cardiac 
dysfunction induced by diabetes. Which may be not related to its potential antioxidant effect. 
Key words: diabetes, 6-gingerol, cardioprotection, adiponectin, vascular complications, 
hemodynamics, electrocardiogram. 
1. Introduction 
Diabetes mellitus (DM) is a common metabolic disorder and a leading cause of 
cardiovascular disease worldwide [1]. The increased morbidity and mortality of these patients 
has been attributed to cardiovascular complications and diabetic cardiomyopathy [2, 3]. Diabetic 
cardiomyopathy (DCM) is pathologic changes in the heart due to diabetes and characterized by 
both structural and functional alterations [4]. These alterations include fibrosis, apoptosis, 
myocyte angiopathy, increased left ventricular (LV) mass and LV hypertrophy and impairment 
in cardiomyocyte contractility with diastolic and systolic dysfunction [5, 6]. Several factors have 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
been suggested to be responsible for the pathogenesis of DCM including hyperglycemia, 
dyslipidemia, insulin resistance, low-grade inflammation, and oxidative stress [7]. 
Despite great advances in treatment of diabetes, natural products with anti-oxidant effects 
may be more favorable for reducing diabetes-induced side effects in many diabetic patients. 
Among plants containing natural anti-oxidants, ginger exhibits antioxidant and anti-
inflammatory properties [8]. Phytochemical studies have indicated that the main constituents of 
ginger extract are the shogaols, gingerols, zingerone and paradol [9]. In addition, 6-gingerol, one 
of the major elements of ginger, has been found to possess antiangiogenic [10], anti-
inflammatory [11], antihyperglycemic [12], and vasorelaxatory effects [13]. Moreover, our 
previous study revealed that 6-gingerol alleviates exaggerated vasoconstriction in diabetic rat 
aorta through direct vasodilation and nitric oxide generation [14]. Therefore, the aim of the 
current study is to investigate the effect of 6-gingerol on alterations in cardiac parameters and 
vascular complications of diabetic rats. 
2. Materials and methods 
2.1.Chemicals 
Streptozotocin (STZ) and 6-gingerol (6G) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), while lipid profile kits were purchased from Randox Laboratories Ltd. (Antrim, UK). 8-
Isopropane assay kit was purchased from Cayman Chemical, Ann Harbor, MI, USA. Tumor 
growth factor beta-1 (TGF-β1) and adiponectin rat enzyme linked immunosorbent assay 
(ELISA) kits was purchased from R&D Systems, Inc., Minneapolis, MN, USA.  
2.2.Animals and experimental protocol 
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Male Wistar rats, 6 weeks age, King Abdulaziz University, Jeddah, Saudi Arabia 
weighting 240-280 gm were housed (3-4 rats per cage) in clear polypropylene cages and kept 
under constant environmental conditions with 12 h day and night cycle, well ventilated, 
temperature 22 ± 2 oC, and relative humidity of 50–60%. Rats had free access to commercially 
available rodent pellet diet and purified water. Care was taken to avoid stressful conditions, and 
all procedures were performed between 8 and 10 a.m. All experimental protocols were approved 
by the Biomedical and research Ethical committee, Faculty of Medicine, King Abdulaziz 
University, Jeddah, Saudi Arabia and were performed in accordance with Saudi Arabia Research 
Bioethics and Regulations, which are consistent with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health. 
Diabetes was induced through single intraperitoneal (i.p.) injection of a fresh solution of 
STZ dissolved in 0.1 M sodium citrate, at a dose of 50 mg/kg, to overnight fasting rats (14, 15]. 
Two weeks after STZ administration, DM rats with blood glucose concentration of between 250–
350 mg/ dL were selected for drug treatment. Based on the results of our previous studies these 
animals will go on to develop vascular complications over the subsequent 8 weeks [14, 16]. 
Age-matched control or the 15-day DM animals were assigned groups with 6-8 animals 
in each group. Group I (normal controls) received an equivalent volume of the 0.1 M sodium 
citrate buffer. Group II (DM) diabetic rats received oral single daily dose of 1% CMC-Na, as a 
vehicle, starting on the 15th day. Group III (DM + 6G) diabetic rats received 6G in a dose of 75 
mg/kg orally as a single daily dose, starting on the 15th day. Group IV (control + 6G), normal 
control rats received 6G in the same dose and duration as in group III.  Animals were maintained 
under standard conditions for a further 8 weeks. 
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At the end of the experiment, animals were fasted for 8 hours and a tail capillary droplet 
was used to determine the fasting blood glucose level. To determine cardiac hemodynamics 
including contractility and conductivity, we followed the same steps previously described in our 
recent work by Azhar and El-Bassossy [17]. For blood analysis, one ml blood was withdrawn 
from the vena cava through a small incision in the lower abdomen and 1ml saline injected to 
prevent hypovolemia.  The blood sample was allowed to coagulate for 30 min at 4°C and 
centrifuged (3000×g, 4°C, 20 min). Serum was divided into aliquots and stored at -20°C for later 
analysis. Rats were then injected with one ml saline to prevent hypovolemia.  At the end of the 
experiment animals were killed by an overdose of anesthetic. 
2.3.Measurement of blood glucose, serum adiponectin and TGF-β, and urinary 8-
isoprostane  
For blood glucose determination, blood was collected from a tail vein after overnight 
fasting, and glucose was measured using a glucometer (ACCU-CHEK®, Roche Diagnostics, 
Mannheim, Germany). Adiponectin and TGF-β1 were measured in serum using rat ELISA kits 
(Quantikine®) according to the manufacturer's protocol.  
For urine collections, rats were placed in individual metabolic cages for a period of 24-h. 
The volume of collected urine was determined gravimetrically and urine samples were kept at 
−80°C until assayed. Urinary 8-isoprostane level was determined by using a sensitive rat enzyme 
immunoassay (EIA) kit (Cayman Chemical, Ann Harbor, MI, USA). 
2.4.Determination of lipid profile 
Total cholesterol (TC), triglycerides (TG) and high density lipoprotein cholesterol (HDL-
C) were determined spectrophotometrically, using commercial kits (ELITech®, ELITech, 
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Puteaux, France). Low density lipoprotein cholesterol (LDL-C) was calculated by using 
Friedewald formula [17]. 
2.5.Cardiac hemodynamic and Electrocardiogram (ECG) recording  
  Invasive cardiac hemodynamics was recorded as previously described in our recent work 
[18]. The BP module identified and calculated the left ventricular end ventricular systolic 
pressure (ESP), left ventricular end-diastolic pressure (EDP), slope of the systolic pressure 
increment (max dP/dt) and slope of the diastolic pressure decrement (min dP/dt), systolic and 
diastolic duration, contractility index and the left ventricular diastolic time constant (Tau).   
The ECG leads I, II, III, aVR, aVL, aVF were recorded with surface skin electrodes (AD 
Instruments, Bella Vista, Australia). Corrected QT (QTc) was calculated with mean values and 
the Bazett’s Formula (QTc = QT Interval/√ (RR interval) [19]. 
2.6.Statistical analysis 
Values are expressed as mean ± SD. Statistical analysis was carried out by using one-way 
analysis of variance (ANOVA) followed by Newman-Keuls’ post hoc test using GrapPad InStat 
statistical software (Prism 5, GraphPad, CA, USA). Significance was measured at p < 0.05. The 
power was greater than 90% with sample sizes of 6-8 rats per group. 
3. Results: 
3.1.Effect of 6G on body weight, biochemical parameters  
A characteristic decrease in body weight and hyperglycemia was observed in the diabetic 
model in the current study. Treatment with 6G was found to ameliorate significantly this 
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hyperglycemia with no significant effect on body weight (figure 1A and 1B). There were no 
significant differences in the lipid profile between different rat groups (table 1).   
Diabetic rats exhibited a significant decrease in serum level of adiponectin when 
compared with control group, although treatment of diabetic rats with 6G had no significant 
effect on serum adiponectin levels (figure 1C) while adiponectin levels were reduced by 6G in 
control normal rats. DM resulted in significantly increased serum TGF-β1 and urinary 8-
isoprostane levels and these increased levels were not significant changed by treatment with 6G 
(figure 1D and 1E). 
 
3.2.Effect of 6G on cardiac hemodynamics 
The present study showed a significant attenuation of max dP/dt, min dP/dt, EDP, and 
ESP in DM rats compared to the nondiabetic control group (figures 2A, B, C and D). Treatment 
with 6G significantly inhibited max dP/dt and min dP/dt changes with no effect on EDP or ESP. 
In contrast, DM rats had no changes in the contractility index (figure 2E) but a significantly 
increased Tau (figure 2F). Despite that, treatment with 6G increased the contractility index 
significantly when compared with DM rats (figure 3E) and significantly alleviated the prolonged 
Tau close to the normal nondiabetic value (figure 2F).         
3.3.Effect of 6G on cardiac ECG parameters 
Diabetic rats study exhibited significant bradycardia with both increased RR and PR 
interval when compared to control nondiabetic animals (figure 3A, B and C). Treatment with 6G 
elicited no significant improvement in bradycardia or RR interval when compared with diabetics 
but did have reduce the PR interval to near normal nondiabetic values (figure 3A, B and C). In 
addition, DM rats showed increased total cycle duration without changing the diastolic duration 
when compared to the normal nondiabetic rats. Treatment with 6G produced no significant 
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differences in total or systolic duration in control or DM rats but increased diastolic duration in 
DM rats (figures 3D, E, and F). 
Moreover, diabetes produced a significant increase in QT, QTc, and JT intervals when 
compared with control nondiabetic rats, and this changes were not significantly changed by 
treatment with 6G (figure 4A, B and C). In contrast, diabetes induced changes in ST height, T 
and R amplitude when compared with control nondiabetic rats (figure 4D, E and F) and these 
changes were significantly attenuated when diabetic rats were treated with 6G.  6G did not 
significantly change ST height, T or R amplitude in controls.  
 
4. Discussion 
In the present study, DM was induced experimentally in rats by STZ injection which was 
evident by a marked and significant hyperglycemia and decrease in body weight. STZ causes 
destruction of β-cells of the pancreas through internalization into the β-cells and liberation of 
toxic nitrosourea and nitric oxide [20].  Hyperglycemia in DM may directly or indirectly enhance 
oxidative stress and associated inflammation, leading to impairment of tissues inducing diabetic 
cardiomyopathy (DCM) and producing abnormal cardiac function [21]. Several previous studies 
have indicated a possible antihyperglyemic effect of the total ginger extract [22, 23]. 6G is one of 
the main constituents of ginger, and this antihyperglycemic action may be due to the antioxidant 
effect of 6G demonstrated in previous studies [24, 25]. 
Ventricular dysfunction in diabetic rats is evident in the current study by a significant 
reduction in in Max dP/dt, Min dP/dt, EDP, ESP and Tau confirming the damaging effects of 
diabetes on cardiac structure and function [26]. Maximum dP/dt is the maximal rate of rise of left 
ventricular pressure and is used often as an expression of myocardial contractility and systolic 
function [27]. In addition, minimum dP/dt can be used as a valuable tool in the evaluation of 
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diastolic function of the left ventricle [28]. Moreover, Weiss et al. [29] found that left ventricular 
diastolic function can be also assessed by an index called left ventricular diastolic time constant, 
or Tau. ESP is used as an indicator also for ventricular contractility and EDP is an indicator for 
preload [30, 31]. 
Previous studies found that hyperglycemia is usually associated with left ventricular 
hypertrophy in type 2 diabetes [32]. In the present study, the increase in R wave amplitude in the 
diabetic rats may indicate a change in left ventricular mass. With diabetes, pathological 
hypertrophy results from myocardial damage and fibrosis [33, 34]. Fibrosis may affect the filling 
and contractility of the ventricles leading to cardiac dysfunction [35]. The present study also 
shows that DM produces significant bradycardia with a prolongation of the RR interval. Previous 
investigations indicate an initial stimulation of the sympathetic nervous system in DM but 
prolonged exposure to hyperglycemia and elevated catecholamine levels causes a decrease in 
adrenergic receptors and subsequently bradycardia may occur [36]. This bradycardia was not 
improved with 6G. In addition, PR intervals are widened in diabetic animals and it has been 
reported that this is commonly associated with atrial fibrillation [37]. We demonstrate a 
significant improvement of this prolonged PR interval in diabetic rats treated with 6G. Moreover, 
there was a prolongation of total cycle duration (especially the systolic duration) indicating an 
effect on systolic and contractility function in diabetic rats. As QT interval is dependent on the 
duration of the cardiac cycle, it was also evident in the present study that QT interval was 
prolonged in diabetic rats. The ventricular repolarization abnormalities in the ECG, including T 
wave morphology changes and QT interval prolongation, could be markers of ventricular 
hypertrophy, left ventricular dysfunction or myocardial ischemia [38] and have been associated 
with an increased risk of sudden death [39]. Acute myocardial ischemia increases the duration of 
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QT interval [40].  Several mechanisms have been proposed to be involved in the prolongation of 
the QT interval secondary to acute myocardial ischemia including changes in the myocardial 
response to catecholamine or cholinergic stimulation, modification of calcium or potassium ion 
transport, or intracellular hydrogen concentration changes [41]. In addition, The ST-segment 
elevation is an indicative marker for ischemia [42], which is also evident in the diabetic rats in 
the current study.  
The current results support the concept that the damaging effect of diabetes on the heart 
may be attributed mainly to the ischemic effect on coronary vessels and blood flow evidenced by 
ECG findings. In the present study treatment with 6G was found to prolong the diastolic 
duration, which may improve the coronary filling. During systole, the coronary arteries are 
compressed by ventricular contraction and greatly increase resistance to coronary blood flow. 
Therefore, most coronary blood flow in the left ventricle occurs during diastole [43]. We 
demonstrated improvement in cardiac function (including systolic and diastolic function) in this 
work.  This diabetic model showed a significant decrease in serum adiponectin, and increases in 
both serum TGF-β1 and urinary 8-isoprostane levels when compared to control non-diabetic 
animals. Adiponectin is an antidiabetic, antiatherogenic and anti-inflammatory adipokine [44, 
45]. In addition, it also has a cardioprotective effect [46].  Previous studies found that significant 
reductions in adiponectin in rodent models are associated with a higher incidence of diabetes, 
dyslipidemia, insulin resistance [44, 45], and cardiovascular disease [46]. TGF-β plays an 
important modulatory role in the immune system and it is usually elevated in DM and diabetic 
nephropathy [47, 48]. In addition, the 8-isoprostane is an oxidative marker and formed during the 
free radical-mediated oxidation of arachidonic acid in the cell membrane [49] and is also 
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elevated in diabetic patients [50]. In the current study, treatment with 6G produced no significant 
effect on adiponectin, TGF-β or 8-isoprostane levels. 
In conclusion, the present study demonstrates that oral administration of the ginger 
constituent, 6G, not only alleviates the hyperglycemia in diabetic rats but also can ameliorates 
and improve the cardiac dysfunction induced by diabetes. This ameliorative effect is evident by 
improving contractility parameters and ischemia evident in ECG through a mechanism which is 
probably not related to its potential antioxidant effect. 
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Table 1: The effect of 6-gingerol (6G) treatment on lipid profiles of diabetes rats (DM) and 
normal controls including total cholesterol (TC), low density lipoprotein (LDL-C), high density 
lipoprotein (HDL-C), and triglycerides (TG). 
 TC LDL-C HDL-C TG 
Control 
DM  
DM + 6G 
Control + 6G 
64.38 ± 12.05 
77.18 ± 17.65  
75.74 ± 20.98 
69.89 ± 8.64 
50.49 ± 14.78  
57.92 ± 14.45  
56.92 ± 16.63  
54.33 ± 7.05 
5.804 ± 2.10  
6.472 ± 1.65  
6.914 ± 1.63  
8.744 ± 2.27 
42.20 ± 10.38 
45.29 ± 17.33  
36.52 ± 7.18  
37.48 ± 11.61 
Values are expressed as the mean ± SD; N=6-8 animals with no significant differences detected 
by One Way ANOVA. 
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Figure legends 
Figure 1: The effect of 6-gingerol (6G) treatment on body weight (A), blood glucose level (B) 
serum adiponectin (C), serum TGF-β1 (D), and urinary 8-isoprostane (E) levels in diabetes (DM) 
and normal control rats 
Values are expressed as the mean ± SD; N=6-8 animals. *P<0.05 compared with the 
corresponding control group values; #P<0.05 compared with the corresponding DM group 
values.  Data were analysed using one-way ANOVA and Newman-Keuls post-hoc test. 
 
Figure 2: The effect of 6-gingerol (6G) treatment in diabetes rats (DM) and normal control rats 
on (A) end diastolic pressure (EDP), (B) end systolic pressure, (C) Peak positive pressure (Max 
dP/dt), (D) Peak negative pressure (Min dP/dt), (E) contractility index and (F) left ventricular 
diastolic time constant (Tau). 
Values are expressed as the mean ± SD; N=6-8 animals. *P<0.05 compared with the 
corresponding control group values; #P<0.05 compared with the DM group. 
Data were analysed using one-way ANOVA and Newman-Keuls post hoc test. 
 
Figure 3: The effect of 6-gingerol (6G) treatment in diabetes rats (DM) and normal control rats 
on heart rate (A), R-R interval (B), P-R interval (C), cycle duration, (D), systolic duration (E), 
and diastolic duration (F). 
Values are expressed as the mean ± SD; N=6-8 animals. *P<0.05 compared with the 
corresponding control group values; #P<0.05 compared with the DM group. Data were analysed 
by using one-way ANOVA and Newman-Keuls post hoc test. 
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Figure 4: The effect of 6-gingerol (6G) treatment in diabetes rats (DM) and normal control rats 
on QT interval (A), corrected QT (QTc) interval (B), JT interval (C), ST height (D), T amplitude 
(E), and R amplitude (F). 
Values are expressed as the mean ± SD; N=6-8 animals. *P<0.05 compared with the 
corresponding control group values; #P<0.05 compared with the DM group. Data were analysed 
by using one-way ANOVA and Newman-Keuls post hoc test. 
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